Dapagliflozin operates as an SGLT2 inhibitor in the renal proximal tubule for glycemic control. Limiting glucose reabsorption facilitates the urinary excretion of excess glucose, assisting in stability.
Dapagliflozin belongs to the class of sodium-glucose co-transporter-2 (SGLT-2) inhibitors. It is designed to reduce the amount of glucose re-absorbed by the kidneys, helping the body eliminate excess sugar through urine. This active compound is a central component of several diabetes treatments, including the brand name product Farxiga.
In Singapore, dapagliflozin-containing tablets are regulated by the Health Sciences Authority (HSA) and are listed under the category of antidiabetic agents. The medication is supplied only after a qualified health professional determines that it fits the patient’s therapeutic plan.
The most common presentation of this agent is an oral tablet, typically supplied in strengths such as 5 mg and 10 mg. Farxiga is marketed as a branded option, while the same molecule is also offered as a generic product by local pharmacies. Tablet forms may differ in shape or coating, but the active ingredient remains identical.
Both the branded version and its generic equivalents are packaged for oral use only. In Singapore, patients receive the medication with standard labeling that outlines dosage ranges, storage instructions, and safety warnings.
These applications are primarily for adult patients whose health profiles indicate potential benefit from reduced glucose re-absorption.
When taken, dapagliflozin blocks the SGLT-2 proteins in the kidney’s proximal tubules. By inhibiting these transporters, the kidney releases more glucose in the urine, which lowers the amount of sugar circulating in the blood. The process also leads to a small loss of water, contributing to modest reductions in blood pressure.
These effects are usually temporary and resolve without medical intervention.
If any of these signs appear, patients should seek prompt medical attention.
For detailed interaction tables, refer to the individual medication’s information sheet.
Store tablets in a dry place at room temperature, away from direct sunlight. The medication is generally prescribed for chronic use, but the duration may vary based on the condition being addressed. Always follow the specific instructions printed on the product label; dosing details differ between Farxiga and its generic equivalents.
This article provides an educational overview of dapagliflozin as an active substance and does not constitute medical advice. Individual medicines containing this molecule, such as Farxiga, may differ in formulation, strength, and specific usage directions. The information presented carries no liability for clinical decisions. For precise dosing, administration, and safety details, patients should consult the labeling of their specific product and seek guidance from a healthcare professional.
